Several human GWAS have identified gene variants in HSD17B13 which generate loss‐of‐function proteins that associate primarily with protection from the severity of MASLD and fibrosis, that is, progression to MASH (Abul‐Husn et al., 2018; Anstee et al., 2020; Luukkonen et al., 2020; Ma et al., 2019; Zhang et al., 2022). Here, HSD17B13 is linked to metabolic dysfunction-associated steatotic liver disease.